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Identification of the matricellular 
protein Fibulin-5 as a target 
molecule of glucokinase-mediated 
calcineurin/NFAT signaling in 
pancreatic islets
Tomoko Okuyama1, Jun Shirakawa1, Hiromi Yanagisawa2, Mayu Kyohara1, Shunsuke 
Yamazaki1, Kazuki Tajima1, Yu Togashi1 & Yasuo Terauchi1
Glucokinase-mediated glucose signaling induces insulin secretion, proliferation, and apoptosis in 
pancreatic β-cells. However, the precise molecular mechanisms underlying these processes are not 
clearly understood. Here, we demonstrated that glucokinase activation using a glucokinase activator 
(GKA) significantly upregulated the expression of Fibulin-5 (Fbln5), a matricellular protein involved 
in matrix-cell signaling, in isolated mouse islets. The islet Fbln5 expression was induced by ambient 
glucose in a time- and dose-dependent manner and further enhanced by high-fat diet or the deletion 
of insulin receptor substrate 2 (IRS-2), whereas the GKA-induced increase in Fbln5 expression was 
diminished in Irs-2-deficient islets. GKA-induced Fbln5 upregulation in the islets was blunted by a 
glucokinase inhibitor, KATP channel opener, Ca2+ channel blocker and calcineurin inhibitor, while it 
was augmented by harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) 1 A 
inhibitor. Although deletion of Fbln5 in mice had no significant effects on the glucose tolerance or β-cell 
functions, adenovirus-mediated Fbln5 overexpression increased glucose-stimulated insulin secretion 
in INS-1 rat insulinoma cells. Since the islet Fbln5 expression is regulated through a glucokinase/KATP 
channel/calcineurin/nuclear factor of activated T cells (NFAT) pathway crucial for the maintenance of 
β-cell functions, further investigation of Fbln5 functions in the islets is warranted.
Glucose metabolism plays an important role in normal β-cell functions such as insulin production and insulin 
secretion, and also in β-cell growth and survival1, 2. Glucose signaling in the pancreatic β-cells has also been 
shown to be involved in β-cell proliferation in both humans and rodents3–6. Glucokinase, a member of the hex-
okinase family, is the predominant enzyme catalyzing the phosphorylation of glucose in the pancreatic β-cells and 
the liver. Glucokinase acts as a glucose sensor for insulin secretion from the pancreatic β-cells7 and is required 
for the effects of glucose signaling on β-cell proliferation8. Heterozygous inactivating mutations of glucokinase 
cause type 2 maturity onset diabetes of the young (MODY2), and homozygous or compound heterozygous inac-
tivating glucokinase mutations cause a more severe phenotype known as permanent neonatal diabetes mellitus 
(PNDM), which manifests at birth9. On the other hand, heterozygous activating glucokinase mutations cause per-
sistent hyperinsulinemic hypoglycemia (PHHI)10, associated with increased β-cell mass and β-cell proliferation11. 
We have shown previously that glucokinase activation ameliorates endoplasmic reticulum (ER) stress-mediated 
apoptosis of the pancreatic β-cells12, while another report revealed that genetic activation of β-cell glucokinase 
causes cell apoptosis associated with DNA double-strand breaks and activation of the tumor suppressor protein 
p5313. Thus, glucokinase appears to play important roles in β-cell function, replication, and survival. These find-
ings inspired the development of a therapeutic strategy for diabetes by targeting glucokinase. Glucokinase acti-
vators (GKAs) increase the glucose affinity and maximum velocity (Vmax) of glucokinase, leading to enhanced 
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glucose-induced insulin secretion from the islets and enhanced hepatic glucose uptake14. This ability suggests a 
potential pharmacological role of GKAs in the treatment of diabetes. However, further investigation is needed to 
determine the efficacy and safety of GKAs; for example, downstream targets of glucose metabolism in the β-cells 
have not yet been clearly revealed.
Fibulin-5 (Fbln5; also known as EVEC or DANCE), a matricellular protein, is essential for elastic fiber assem-
bly15, 16. Fbln5 is secreted by various cell types, including vascular smooth muscle cells (SMCs), fibroblasts and 
endothelial cells. Fbln5 expression is usually downregulated after birth, but reactivated upon tissue injury17, 18. 
Fbln5 has several non-elastogenic functions, for example, regulation of proteases via its integrin-binding 
domain19–22. Fbln5 has also been shown to bind to the α5β1 fibronectin receptor and the β1 integrin21, 23. Indeed, 
Fbln5 plays critical roles in cell proliferation, migration and invasion of certain tumors and smooth muscle cells24, 25. 
Mice lacking in Fbln5 exhibit systemic elastic fiber defects, including loose skin, tortuous aorta, emphysematous 
lungs, and genital prolapse16, 26. However, the precise nature of the involvement of Fbln5 in metabolism remains 
unknown.
In this study, we found that treatment with a GKA induced Fbln5 gene expression in mouse pancreatic islets. 
Although it has been reported that interaction of the islets with some specific extracellular matrix molecules is 
important for islet/β-cell survival27, 28, the precise expression levels and roles of these molecules in the pancreatic 
islets and β-cell functions remain obscure. In this study, we focused on the regulation of Fbln5 expression in the 
pancreatic β-cells.
Results
Glucokinase activation induced Fbln5 expression in the pancreatic islets. At first, we identified 
by gene expression microarray analysis (GSE41248), that stimulation of mouse pancreatic islets with a GKA for 
24 hours induced Fbln5 expression in the islets (12.6-fold enhanced expression as compared to that in the vehicle 
control; p = 0.0043)12. To validate this upregulation of Fbln5 expression by treatment with a GKA in mouse pan-
creatic islets, we investigated Fbln5 mRNA expression in isolated islets from C57BL/6 J mice. Consistent with the 
results of the microarray analysis, the Fbln5 mRNA expression in the isolated islets was significantly increased, in 
a time-dependent manner, by treatment with a GKA (Fig. 1a). Ambient glucose also induced Fbln5 expression in 
the islets in a concentration-dependent manner (Fig. 1b). We detected FBLN5 protein expression in the wild-type 
mouse islets, as well as in INS-1 rat insulinoma cell line (Fig. 1c and d) but not in the Fbln5-deficient (Fbln5−/−) 
islets (Fig. 1c). The treatment with a GKA also increased FBLN5 protein expression levels in INS-1 cells (Fig. 1d). 
Moreover, in glucokinase hetero-deficient (Gck+/−) mouse islets, GKA-stimulated Fbln5 mRNA expression levels 
were reduced as compared to those in the islets from wild-type mice (Fig. 1e). No difference was detected in Fbln5 
mRNA expression levels between vehicle-treated Gck+/− islets and the wild-type islets (p = 0.357) (Fig. 1e). These 
results suggest that Fbln5 expression is induced by glucokinase activation in the pancreatic islets. Furthermore, 
the GKA-induced increase in Fbln5 expression was more pronounced in the islets of mice reared on a high-fat 
diet for 20 weeks than in the islets of standard chow-fed mice (Fig. 1f), although there were no significant differ-
ences between the vehicle-treated islets from standard chow-fed and high-fat diet-fed mice (p = 0.24), consistent 
with the report that glucokinase-mediated signaling in the β-cells is activated by a high-fat diet8, 29. In contrast, 
in insulin receptor substrate 2 (IRS-2)-deficient (Irs-2−/−) mouse islets, basal Fbln5 expression was significantly 
increased compared with those of wild-type mice (Fig. 1g). However, the response of Fbln5 induction to GKA 
was almost abolished in Irs-2−/− mouse islets (Fig. 1g). It may also explain the more pronounced upregulation of 
islet Fbln5 expression in high-fat diet-fed mice than in normal chow-fed mice, as GKA is known to induce IRS-2 
expression in the β-cells of mice reared on a high-fat diet8. The lack of Fbln5 induction in Irs-2−/− islets suggests 
that IRS-2 is involved in the GKA-induced upregulation of islet Fbln5 expression. Moreover, we found that Fbln5 
was strongly expressed in the islets of 2-week-old pre-weaning mice, the expression level decreasing by 6 or 12 
weeks of age (Fig. 1h). This expression pattern of Fbln5 is consistent with the expression of the proliferation 
marker Ki67 in the islets (Fig. 1i).
Glucokinase/KATP channel/calcineurin/NFAT signaling is required for glucose-mediated Fbln5 
expression in islets. We next assessed the signaling pathways underlying the GKA-induced upregulation of 
Fbln5 in the pancreatic islets. Treatment with D-mannoheptulose, a specific inhibitor of glucokinase, completely 
abolished the GKA-induced upregulation of Fbln5 in the pancreatic islets (Fig. 2a). In addition, treatment with 
diazoxide, a KATP channel (ATP-sensitive potassium channel) opener, also suppressed the GKA-induced elevation 
of Fbln5 expression in the islets (Fig. 2b). Treatment with OSI-906, a dual insulin and IGF-1 receptor inhibitor, 
did not reduce the Fbln5 induction by GKA, but enhanced it (Fig. 2c). These results imply that an influx of Ca2+ 
into the β-cells via depolarization of the plasma membrane accompanied by the closure of KATP channel, and not 
the autocrine action of insulin, is involved in the GKA-induced upregulation of Fbln5 in the pancreatic islets.
Calcineurin is activated in an intracellular Ca2+-dependent manner30, leading to NFAT activation by dephos-
phorylation and subsequent translocation of NFAT from the cytosol to the nucleus31. Glucose-induced regulation 
of Irs-2 expression has been reported to be mediated via this Ca2+/calcineurin/NFAT signaling in the pancreatic 
β-cells32. Hence, we evaluated the effects of a Ca2+ channel blocker, a calcineurin inhibitor, and a DYRK1A inhib-
itor on the upregulation of Fbln5 in the islets treated with a GKA. Blockade of the L-type voltage-dependent Ca2+ 
channels (L-type VDCCs) with nifedipine in isolated mouse islets abrogated the GKA-induced increase in Fbln5 
expression in the islets (Fig. 2d). Moreover, treatment with FK506, which specifically inhibits calcineurin activity, 
also almost completely abolished the GKA-induced increase in Fbln5 expression in the pancreatic islets (Fig. 2d). 
Dual-specificity tyrosine phosphorylation-regulated kinases (DYRKs), including DYRK1A, inactivate the NFAT1 
proteins by phosphorylating its SP-3 motif33. Notably, harmine, a DYRK1A inhibitor, enhanced the Fbln5 expres-
sion induced by treatment with a GKA (Fig. 2e). The effect of harmine on the increment in Fbln5 expression in 
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Figure 1. Glucokinase activation was associated with upregulation of Fbln5 gene expression in pancreatic islets. 
(a) Fbln5 mRNA expression levels in isolated islets from C57BL/6 J mice incubated for 2, 6, 12 and 24 hours 
with 30 μmol/L of GKA CpdA or vehicle (DMSO) (n = 4). (b) Fbln5 mRNA expression levels in isolated 
islets from C57BL/6 J mice (n = 4) after 24 hours’ incubation with 2.8, 5.6, 11.1 or 22.2 mmol/L of glucose. (c) 
Immunoblotting for FBLN5 in islets isolated from wild-type or Fbln5−/− mice. Full-length blots are presented 
in Supplementary Fig. 4. (d) Immunoblotting for FBLN5 in INS-1 cells treated with vehicle, 22.2 mmol/L of 
glucose, or 30 μmol/L of GKA CpdA for 24 hours (n = 4). Full-length blots are presented in Supplementary 
Fig. 4. (e) Fbln5 mRNA expression levels in islets from 12-week-old Gck+/− mice and their wild-type littermates 
after incubation with 30 μmol/L of GKA CpdA for 24 hours (n = 4). (f) Fbln5 gene expression levels in islets 
isolated from 12-week old standard chow-fed mice (SC) and 20-week of high-fat diet (HFD)-fed mice incubated 
with or without 30 μmol/L of GKA CpdA (vehicle; DMSO) for 24 hours (n = 4). (g) Fbln5 mRNA expression 
levels in islets from 12-week-old Irs-2−/− mice and their wild-type littermates after incubation with 30 μmol/L of 
GKA CpdA for 24 hours (n = 4). (h–i) mRNA expression levels of Fbln5 (h) or Ki67 (i) in isolated islets from 2-, 
6- and 12-week-old C57BL/6 J mice (n = 3–4). Data are represented as means ± SEM. *p < 0.05, **p < 0.01.
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islets was blunted in the presence of FK506 (Fig. 2f). These results suggest that the transcriptional regulation of 
Fbln5 in the islets is mediated by glucose signaling and downstream Ca2+/calcineurin/NFAT signaling.
Fbln5−/− mice exhibited normal glucose tolerance and normal glucose-stimulated insulin secre-
tion and β-cell proliferation evoked by GKA. To investigate the role of Fbln5 in glucose metabolism and 
insulin secretion, we used 8- to 12-week-old Fbln5 knockout (Fbln5−/−) mice16 to evaluate whether Fbln5 deletion 
may influence glucose homeostasis in vivo. Fbln5−/− mice showed normal glucose tolerance and comparable insu-
lin secretion during an oral glucose tolerance test (Fig. 3a and b). No significant difference in glucose-stimulated 
insulin secretion was observed between islets isolated from Fbln5−/− mice and wild-type mice (Fig. 3c). These 
results imply that Fbln5 has no effect on insulin secretion in healthy young adult mice.
We next assessed the β-cell mass in the 8- to 12-week-old Fbln5−/− mice. No significant differences in the 
islet morphology and the β-cells area relative to the total pancreatic area were observed between the wild-type 
mice and Fbln5−/− mice (Fig. 3d and e). Furthermore, we evaluated the GKA-induced β-cell proliferation activity 
Figure 2. Glucose-signal induced Fbln5 upregulation via the glucokinase/KATP channel/calcineurin/NFAT 
signaling pathway in pancreatic islets. (a–f) Fbln5 mRNA expression. Islets from C57BL/6 J mice were incubated 
with 10 nmol/L of D-mannoheptulose (MH) (n = 4) (a), 200 μmol/L of diazoxide (n = 4) (b), 200 nmol/L of 
OSI-906 (n = 4) (c), 50 μmol/L of nifedipine (ND), 10 μmol/L of FK506 (n = 3) (d), 10 μmol/L of harmine 
(n = 3) (e), or a combination of 10 μmol/L of FK506 and 10 μmol/L of harmine (n = 4) (f) for 24 hours in the 
presence or absence of 30 μmol/L of GKA CpdA (vehicle; DMSO). Data are represented as means ± SEM. 
*p < 0.05, **p < 0.01.
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in Fbln5−/− and wild-type islets. Treatment with GKA for 48 hours markedly increased the EdU-incorporated 
proliferating insulin-positive β-cells to a similar extent in the islets isolated from both genotypes of mice (Fig. 3f 
and g). On the other hand, the fluorescent intensity of insulin was significantly increased in the GKA-treated 
islets compared with the vehicle-treated islets in wild-type mice, but not in Fbln5−/− mice (see Supplementary 
Fig. S1a). This result in islets from wild-type mice is consistent with the observation that glucokinase activation 
enhances insulin gene expression and insulin secretion in β-cells12, 34. However, GKA-induced insulin secretion 
was not decreased in Fbln5−/− islets compared with wild-type islets (see Supplementary Fig. S1b). Insulin content 
Figure 3. Fbln5 deficiency in mice had no effect on glucose tolerance, glucose-stimulated insulin secretion 
or β-cell proliferation. (a) Blood glucose levels during an oral glucose tolerance test (OGTT) in 8-week-old 
Fbln5−/− mice and wild-type mice (1.5 g/kg body weight, n = 11–13). (b) Serum insulin levels during the OGTT 
(n = 11–13). (c) Glucose-stimulated insulin secretion in ten isolated islets from 8-week-old Fbln5−/− mice 
and wild-type mice (n = 6–12). (d,e) β-cell mass in 8-week-old Fbln5−/− mice and wild-type mice (n = 5). 
Representative images of the pancreas showing brown staining of insulin (d) and the ratio of the β-cell mass 
relative to the area of the whole pancreas (e) (n = 5). The scale bar represents 100 µm in the pancreas images. 
(f,g) EdU incorporation in islets isolated from 8-week-old C57BL/6 J mice. Representative images of pancreatic 
islets after 48 hours of incubation with EdU in the presence or absence of 30 μmol/L of GKA CpdA (f). Insulin 
is stained red, nuclei are stained blue with 4′, 6-diamidino-2-phenylindole [DAPI], and EdU-positive nuclei are 
stained green. The white arrows indicate EdU-positive β-cells. The scale bar represents 50 µm. The ratio of EdU-
positive β-cells to the total count of insulin-positive β-cells is shown (g). More than 3000 cells were counted in 
each group (n = 2). Data are represented as means ± SEM. *p < 0.05.
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in GKA-treated Fbln5−/− islets showed a tendency to be decreased compared to wild-type islets, but it did not 
reach statistical significance (see Supplementary Fig. S1b). Thus, Fbln5 is not required for the development and 
maintenance of β-cell function or proliferation.
In immunohistochemical analysis of paraffin-embedded endocrine pancreatic tissue from 8-week-old 
wild-type mice and Fbln5−/− mice, FBLN5 was seemed to be around CD34 (endothelial marker) -positive inter-
stitial tissue, but not in β-cells, α-cells, or δ-cells in the islets (see Supplementary Fig. S2). Next, fetal pancreatic 
tissue paraffin sections from wild-type mice at the age of embryonic day 15 were immunostained for FBLN5. The 
area and intensity of the FBLN5 signal in the islets seemed to be more abundant compared with those in adult 
mice (see Supplementary Fig. S3a). Then, we used non-paraffinized cultured islets from 8-week-old wild-type 
mice for immunostaining. Notably, FBLN5-positive β-cells were detectable in non-paraffinized adult wild-type 
islets (see Supplementary Fig. S3b). In addition, FBLN5 is observed at cytoplasmic granular structures in INS-1 
cells, as shown in Supplementary Fig. S3c, suggesting that FBLN5 is also expressed in β-cells.
Adenovirus-mediated Fbln5 overexpression increased glucose-stimulated insulin secretion and 
inhibited cell proliferation in INS-1 cells. Next, we evaluated the properties of Fbln5 by forced expression 
of Fbln5 gene expression using an adenovirus vector (Ad-Fbln5) in INS-1 cells. Following adenovirus-mediated 
infection of Ad-Fbln5 in INS-1 cells, overexpression of Fbln5 was confirmed by measuring the mRNA and pro-
tein expression levels (Fig. 4a and b). The cells overexpressing Fbln5 showed enhanced insulin secretion in the 
presence of 11.1 mmol/L glucose as compared to the control cells (1.6-fold, p = 0.017), although basal insulin 
secretion was not significantly different between the Ad-Fbln5- and Ad-GFP- infected INS-1 cells (Fig. 4c). The 
effects of Fbln5 overexpression on the cell proliferation activity was evaluated by measuring the EdU incorpo-
ration and Ki67 expression in Ad-Fbln5-infected INS-1 cells. We were almost able to ignore the GFP-signals 
when we adjusted the gain of signals according to the fluorescent intensity of EdU. (Fig. 4d left panel). The ratio 
of EdU-incorporated proliferating INS-1 cells to the total count of INS-1 cells tended to be decreased in the 
Ad-Fbln5-infected cells as compared with that in the control cells (Fig. 4d). In addition, Ad-Fbln5-infected INS-1 
cells showed significant reduction in the Ki67 expression (Fig. 4e). These results indicate that overexpression of 
Fbln5 enhances insulin secretion whereas decreases cell proliferation in β-cells.
Discussion
In this study, we showed the glucose signaling-induced transcriptional regulation of Fbln5 in pancreatic islets, 
which is mediated by glucose metabolism via glucokinase and downstream Ca2+/calcineurin/NFAT signaling 
pathway (Fig. 5).
Because β-cells are exposed to high ambient glucose concentrations under the diabetic condition, glucokinase, 
which acts as a glucose sensor, transmits the impact of the hyperglycemia to the β-cells. In the pancreatic islets, 
glucokinase is mainly expressed in the β-cells, with very low levels of expression observed in the α-cells (unpub-
lished data). We confirmed GKA-induced increase in FBLN5 expression in INS-1 cells. Immunohistochemical 
analysis of INS-1 cells also supported that FBLN5 is expressed in the β-cells. However, further investigation using 
more specific antibody is needed to clarify the localization of FBLN5 since we observed FBLN5 signal not only in 
cytoplasm but also in the nucleus in INS-1 cells. FBLN5 immunofluorescence from paraffin-embedded tissue was 
mainly detected in non-β-cells tissue in the islets. FBLN5 is reported to be deposited on microfibrils during the 
development of mature elastic fiber26. Co-staining FBLN5 with CD34 in islets from paraffin-embedded specimens 
indicated that FBLN5 is strongly expressed in endothelial cells or small vessels in islets, consistent with the previ-
ous reports, which showed FBLN5 secretion from vascular smooth muscle cells or endothelial cells35, 36. FBLN5 
was also detectable in β-cells in the non-paraffinized cultured islets. It is therefore possible that FBLN5 in β-cells 
was lost or masked in the process of paraffin embedding or deparaffinization. Since dual inhibition of insulin 
and IGF-1 receptor with OSI-906 did not abrogate GKA-induced Fbln5 upregulation in the islets, it is unlikely 
that this upregulation is mediated by an autocrine action of insulin on the insulin receptor. Because FBLN5 is a 
secreted protein, islet-derived FBLN5 might be deposited outside of the islets and play a role in non-islet tissue 
functions.
Our data showed that GKA-induced upregulation of Fbln5 was more pronounced in islets isolated from obese 
mice reared on a high-fat diet than in the islets of control mice fed normal chow. This could be explained by the 
involvement of glucokinase in the compensatory β-cell hyperplasia induced by a high-fat diet8, 29. Consistent 
with this notion, we found that Irs-2 deletion increased basal Fbln5 expression and attenuated the GKA-induced 
upregulation of Fbln5 in the isolated islets. Chronic hyperglycemia in Irs-2−/− mouse may cause the elevation 
in Fbln5 in the islets at the basal state. Other factors that are related to insulin resistance with Irs-2 deletion in 
mice can possibly be involved in this basal elevation. Glucose-induced transcriptional regulation of Irs-2 gene 
expression in the β-cells is mediated by the Ca2+/calcineurin/NFAT pathway32, which is involved in β-cell pro-
liferation in mice and humans37, 38. In addition, the DYRK1A inhibitor has been demonstrated to enhance β-cell 
proliferation in mice39, 40. It is also reported that GKA-induced increase of the mRNA expressions of Nfatc1 and 
its downstream genes are involved in β-cell maturation and β-cell proliferation in neonatal islets38. A recent study 
showed that glucose-induced mouse pancreatic β-cell proliferation is mediated via IRS-2, MTOR and cyclin D2, 
but not by the insulin receptor41. We also found that the Fbln5 expression was higher in the islets harvested from 
pre-weaning mice, which showed robust β-cell proliferation as confirmed by the high Ki67 expression. Fbln5 is 
strongly expressed during embryogenesis and plays a role in tissue remodeling25. Therefore, Fbln5 could be a 
predictor for compensatory β-cell proliferation and remodeling of β-cell mass induced by activation of IRS-2 
expression.
How does NFAT signaling regulate the transcriptional activity of Fbln5 ? Fbln5 expression is positively regu-
lated via transforming growth factor β1 (TGF-β1) in fibroblasts or epithelial cells25. Calcineurin inhibitors induce 
the TGF-β receptor-triggered signaling cascade in the mesangial cells or kidney42. Hypoxia-inducible factor-1α 
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(HIF-1α) is also a Fbln5-inducible factor in the endothelial cells43. HIF-1α expression is also reportedly regulated 
through calcineurin activity or dephosphorylation of RACK1 in mast cells44, 45. We have identified NFAT consen-
sus sequences in the 5-upstream region of the mouse Fbln5 gene at: −698 to −693 (AGGAAA), +386 to +391 
(TGGAAA), +428 to +433 (TGGAAA), +591 to +596 (TGGAAA), and 4 other sites from the first transcription 
initiation site. Further analysis, including of the TGF-β and HIF-1α pathways, are needed to clarify the precise 
mechanism of Fbln5 transcription via NFAT in pancreatic islets.
Loss of systemic Fbln5 expression had no significant effects on the insulin secretion from the pancreatic islets 
or β-cell proliferation/expansion in young adult mice, suggesting that Fbln5 does not seem to be involved in β-cell 
Figure 4. Fbln5 overexpression in INS-1 cells enhanced glucose-stimulated insulin secretion, but inhibited 
β-cell proliferation. (a) Fbln5 mRNA levels in INS-1 cells after infection with Ad-GFP or Ad-Fbln5 for 48 hours 
(n = 2). (b) Immunoblotting for FBLN5 in INS-1 cells infected with Ad-GFP or Ad-Fbln5. Full-length blots 
are presented in Supplementary Fig. 4. (c) Glucose-stimulated insulin secretion by INS-1 cells infected with 
Ad-GFP or Ad-Fbln5 (n = 6–12). (d) EdU incorporation in INS-1 cells infected with Ad-GFP or Ad-Fbln5 for 
48 hours. Cells were incubated for 3 hours with 10 µM of EdU after adenovirus infection. left: Representative 
images of Ad-GFP infected INS-1 cells or Ad-Fbln5 infected INS-1 cells stained for EdU. Ad-GFP infected 
cells incubated without EdU are shown as control. Insulin is stained red, nuclei are stained blue with DAPI, 
and EdU-positive nuclei are stained green. The scale bar represents 50 µm. right: The ratio of EdU-positive cells 
to the total count of insulin-positive cells is shown. More than 6000 cells were counted in each group (n = 4). 
(e) Ki67 mRNA expression in INS-1 cells infected with Ad-Fbln5 or Ad-GFP for 48 hours (n = 4). Data are 
represented as means ± SEM. *p < 0.05.
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development or functions at this stage of life. However, the effects of Fbln5 on pancreatic β-cell functions under 
diabetic- or insulin-resistant conditions remain unclear. In addition, we showed that Fbln5 expression is abun-
dant in the islets from fetal or pre-weaning mice. Testing juvenile mice, therefore, is required for further investi-
gation into the physiological role of Fbln5 in the context of developmental process. Fbln5 overexpression in INS-1 
cells revealed that Fbln5 could positively regulate glucose-stimulated insulin secretion from the pancreatic β-cells. 
By contrast, Fbln5 overexpression possibly suppress cell proliferation in the INS-1 cells. In fact, Fbln5 overexpres-
sion decreased Ki67 expression in INS-1 cells, although Fbln5 and Ki67 expression were increased in proliferat-
ing juvenile islets. Fbln5 is reported to promote cell proliferation or tumor growth in mouse 3T3-L1 fibroblasts 
or human HT1080 fibrosarcoma cells25, mouse pancreatic ductal adenocarcinoma46, and human gastric cancer 
MGC-803 cells47. On the other hand, several previous studies have demonstrated inhibition of cell proliferation 
by Fbln5 overexpression in mouse vascular smooth muscle cells18, human breast cancer cells48, mink lu Mv1Lu 
epithelial cells25, primary human saphenous vein endothelial cells49, and rat retinal pigment epithelial cells50. 
Thus, further investigation of the pathway that mediate Fbln5 action on β-cell proliferation is required. These 
effects of Fbln5 on β-cell functions and β-cell proliferation might be explained by the distinct proliferative and 
functional state of the β-cells. A previous study showed that a high rate of insulin production suppressed β-cell 
proliferation because of increased ER stress, in a cell-autonomous manner51. On the other hand, genes involved 
in β-cell functions were suppressed when proliferation-related genes were upregulated in replicating β-cells52.
There is a report in the literature which suggests that another matricellular protein, SPARC, which is expressed 
in stromal cells within the islets, can regulate β-cell growth and survival by inhibiting growth factor responses53. 
Thus, the interactions between Fbln5 and pancreatic β-cell functions, which are still poorly understood, may rep-
resent novel molecular mechanisms involved in glucose metabolism and provide new insights for the treatment 
in diabetes.
Figure 5. A schematic representation of glucokinase-mediated Fbln5 expression in pancreatic islets. Fbln5 
gene expression was induced by glucokinase activation through ambient high glucose concentrations or GKA 
in pancreatic islets. Depolarization of the membrane accompanied by the closure of KATP channels, Ca2+ influx 
and calcineurin activation are required for this Fbln5 upregulation. A DYRK1A inhibitor, harmine, enhanced 
Fbln5 expression in the islets induced by glucokinase activation, possibly via NFAT signaling. DYRK1A; 
dual-specificity tyrosine phosphorylation-regulated kinase 1 A, GKA; glucokinase activator, KATP channel; 
ATP-sensitive potassium channel, NFAT; nuclear factor of activated T cells, VDCC; voltage-dependent Ca2+ 
channels.
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In summary, we demonstrated that expression of the matricellular protein Fbln5 is upregulated by high ambi-
ent glucose concentrations in the pancreatic islets though glucokinase-dependent glucose and downstream Ca2+/
calcineurin/NFAT signaling. Further study of the regulation of islet Fbln5 expression is warranted, especially in 
relation to glucose signaling and proliferation of β-cells.
Methods
Animals and Animal Care. All the animal procedures were performed in accordance with the guidelines 
of the Animal Care Committee of Yokohama City University. The protocol was approved by the Yokohama City 
University Institutional Animal Care and Use Committee (IACUC) (Permit Number: F-A-16-026). C57BL/6 J 
mice were purchased from Jackson. We backcrossed Fbln5 knockout (Fbln5−/−) mice16, 19 with C57BL/6 J mice 
more than 10 times. Both Fbln5−/− mice and wild-type littermates were fed a standard chow (MF, Oriental Yeast, 
Tokyo, Japan) or a high-fat diet (Clea Japan, Tokyo, Japan). All the experiments were conducted on male lit-
termates. Animal housing rooms were maintained at a constant room temperature (25 °C) and a 12-hour light 
(7:00 a.m.) /dark (7:00 p.m.) cycle.
Adenovirus. Fbln5-overexpressing recombinant adenovirus (Ad-Fbln5)18 and GFP-expressing control ade-
novirus (Ad-GFP) were used for the experiments at a multiplicity of infection of 50 viruses per cell. In brief, the 
FLAG-tagged full-length rat Fbln5 was inserted in an adenoviral vector (pACCMVpLpA(−) loxP-SSP). Viruses 
were generated by transfection into the Human Embryo Kidney 293 (HEK293) cell line.
Islet isolation and culture. Isolation of islets from mice was conducted using collagenase, as described in 
a previous report54. The isolated islets were cultured in RPMI 1640 medium (Wako Pure Chemical Industries) 
containing 5.6 mmol/L glucose supplemented with 10% FCS, 100 units/mL of penicillin, and 100 μg/mL of strep-
tomycin. The islets were treated with 30 μmol/L of GKA Cpd A, 50 μmol/L of nifedipine, 10 μmol/L of FK506, 
10 μmol/L of D-mannoheptulose (Toronto Research Chemicals), 200 μmol/L of diazoxide (Wako Pure Chemical 
Industries), 200 nmol/L of OSI-906 (Selleck Chemicals). All the reagents were added concomitantly to the 
medium in each experiment.
Oral glucose tolerance test. All the mice were denied access to food for 14–16 hours before the oral glu-
cose tolerance test (OGTT) and then orally loaded with glucose at 1.5 mg/g body weight. Blood glucose levels and 
serum insulin levels were determined using Glutest Neo Super (Sanwa Chemical Co. Kanagawa, Japan) and an 
insulin ELISA kit (Morinaga Institute of Biological Science, Yokohama, Japan), respectively.
Glucose-stimulated insulin secretion in isolated islets and INS-1 cells. Ten islets isolated from 
Fbln5−/− mice and wild-type mice were incubated at 37 °C for 1.5 hours in Krebs-Ringer bicarbonate buffer con-
taining 2.8, 11.1 or 22.2 mmol/L of glucose. When examining the effect of Fbln5 deficiency on GKA-induced 
insulin secretion, islets were incubated at 37 °C for 1.5 hours in Krebs-Ringer bicarbonate buffer containing 
2.8 mmol/L glucose with or without 30 µmol/L of GKA CpdA, or 11.1 mmol/L glucose without GKA CpdA. For 
measuring insulin content, islets were extracted with acid ethanol. INS-1 cells were infected with adenovirus 
(Ad-GFP or Ad-Fbln5) and cultured for 48 hours. Subsequently, the cells were incubated at 37 °C for 2 hours in 
Krebs-Ringer bicarbonate buffer containing 2.8, 11.1 or 22.2 mmol/L of glucose. Then, the insulin concentration 
in the assay buffer and insulin content was measured with an insulin ELISA kit.
Cell culture. INS-1 (832/13) cells55 were cultured in RPMI 1640 containing 10 mmol/L of HEPES, 
11.1 mmol/L of glucose, 10% FBS, 1 mmol/L of sodium pyruvate, 2 mmol/L of L-glutamine, 50 μmol/L of 
2-mercaptoethanol, 100 units/mL of penicillin and 100 μg/mL of streptomycin. The cells were maintained at 
37 °C in humidified air containing 5% CO2. Before the experiments, the INS-1 cells were starved by incubation in 
RPMI1640 medium containing 2.8 mmol/L of glucose, 100 units/mL of penicillin, and 100 μg/mL of streptomycin 
for 16 hours.
Histological analysis. Pancreatic tissue sections from embryonic day15 and 8-week-old Fbln5−/− mice 
and wild-type mice were analyzed after formalin fixation and paraffin embedding. For non-paraffinized tissue 
staining, isolated islets from 8-week-old wild-type mice attached to 0.1%-gelatin-coated coverslips (Falcon) were 
analyzed after fixation with paraformaldehyde. Pancreatic islets isolated from 8-week-old wild-type mice were 
analyzed after fixation without paraffin embedding. The sections or attached islets on coverslips were immu-
nostained with antibody directed against insulin (Santa Cruz Biotechnology), glucagon (Abcam), somatosta-
tin (GeneTex), CD34 (Santa Cruz Biotechnology), or rabbit polyclonal anti-fibulin-5 (BSYN 1923; 1:100)16. 
FBLN5 signal was enhanced by tyramide signal amplification, using a TSA Fluorescein System (Perkin Elmer, 
NEL741001KT), in paraffin-embedding sections. Biotinylated secondary antibodies, a VECTASTAIN Elite 
ABC Kit, and a DAB Substrate Kit (Vector Laboratories) were used to examine the sections using bright-field 
microscopy to determine the β-cell mass, and Alexa Fluor 488-, 555- and 647-conjugated secondary antibod-
ies (Invitrogen) were used for the fluorescence microscopy. Images were acquired using a BZ-9000 microscope 
(Keyence) or the FluoView FV1000-D confocal laser scanning microscope (Olympus). The proportion of the area 
of the pancreatic tissue occupied by β-cells was calculated using BIOREVO software (Keyence), as described pre-
viously56. The fluorescence levels of insulin in GKA-treated wild-type and Fbln5−/− islets were determined using 
Image J software. All images, which were acquired under the same condition, were converted to gray scale. Then, 
we randomly selected 5 regions of separate islets in each group and measured fluorescence levels. The fluorescent 
intensity were normalized by the mean background fluorescence levels.
www.nature.com/scientificreports/
1 0Scientific RepoRts | 7: 2364  | DOI:10.1038/s41598-017-02535-0
Proliferation Assay. Isolated islets from Fbln5−/− mice and wild-type mice were incubated with a modified 
thymidine analog, EdU (5-ethynyl-2’-deoxyuridine; Click-iT EdU; Invitrogen Cat. No. C10637) in the presence 
or absence of 30 μmol/L of GKA. After the treatment for 48 hours, the islets were fixed and sections were prepared 
of the embedded islets in 1% agarose-gel.
INS-1 cells were infected with an adenovirus vector (Ad-GFP or Ad-Fbln5) and cultured for 48 hours. Then, 
the cells were incubated with 10 µM of EdU for 3 hours and fixed. EdU incorporation and detection were per-
formed as described in the manufacturer’s protocol. The images were taken using the FluoView FV1000-D 
confocal laser scanning microscope. We counted EdU-positive proliferative cells after adjusting the gain of fluo-
rescence. At that condition there were no significant changes in the fluorescent intensity between GFP-positive 
cells and GFP-negative cells.
Real-time PCR. Total RNA was isolated from the pancreatic islets using an RNase-free DNase and RNeasy 
Kit (Qiagen, Valencia, CA). cDNA was prepared using High Capacity cDNA Reverse-Transcription Kits (Applied 
Biosystems). Quantitative PCR was performed by using TaqMan Gene Expression Assays (7900 Real-Time PCR 
System; Applied Biosystems) with the THUNDERBIRD qPCR Master Mix (TOYOBO). All the probes were pur-
chased from Applied Biosystems (mouse Fbln5; Mm00488601_m1, mouse β-actin; Mm00607939_s1, mouse 
Ki67; Mm01278617_m1, rat Fbln5; Rn0069712_m1, rat β-actin; Rn00667869_m1, rat Ki67; Rn01451446_m1). 
Data were normalized to the expression level of β-actin.
Immunoblotting. For immunoblotting, isolated mouse islets and INS-1 cells were lysed in ice-cold RIPA 
buffer with protease and phosphatase inhibitor cocktail. The islets and cell extracts were subjected to immu-
noblotting. The primary antibodies used were rabbit anti-FBLN5 (BSYN1923) at the dilution of 1:100, or 
Anti-Fibulin-5-Antibody (Millipore) at the dilution of 1:5000, and β-actin (Sigma-Aldrich). Densitometry was 
performed using Image J software.
Statistical analysis. All the data are expressed as the means ± SEM, and were analyzed using the Student’s 
t test or ANOVA. Differences between two groups were analyzed by Student’s t test (Figs 1a, 3b-c and e, 4, 
Supplementary Fig. S1b-c). For comparisons among more than two groups, we used the one-way ANOVA fol-
lowed by the Tukey HSD post hoc test (Figs 1b and d–i, 2a and d, 3g, Supplementary Fig. S1a). When the data had 
unequal variance, we used Welch’s one-way ANOVA followed by the Games-Howell post hoc test (Fig. 2b,c,e,f). 
Differences were considered significant if the p value was <0.05 (*) or <0.01 (**).
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